Table 1. Open in new tab Patients and... | Oxford Academic

Table 1.

Open in new tab

Patients and Disease Characteristics

Patient and disease characteristics	Value
Age, years (range)^a	49 (21-69)
Mean BMI (kg/m²)^a	22
Current smoking history n (%)^a	6 (9.5)
Diabetes n (%)^a	8 (10)
Axillary lymph node dissection n (%)	18 (28.5)
Previous radiotherapy n (%)^a	4 (5.4)
Post mastectomy radiotherapy n (%)	11 (14.8)
Neoadjuvant chemotherapy n (%)	15 (23.8)
Adjuvant chemotherapy n (%)	21 (33.3)
Previous surgery n (%)^a	4 (6.3)
Multicentric/multifocal disease n (%)^a	23 (33.3)
Hormone receptor status positive n (%)^a	51 (73.9)
Clinical presentation (palpable/not palpable)^a	42/32

Patient and disease characteristics	Value
Age, years (range)^a	49 (21-69)
Mean BMI (kg/m²)^a	22
Current smoking history n (%)^a	6 (9.5)
Diabetes n (%)^a	8 (10)
Axillary lymph node dissection n (%)	18 (28.5)
Previous radiotherapy n (%)^a	4 (5.4)
Post mastectomy radiotherapy n (%)	11 (14.8)
Neoadjuvant chemotherapy n (%)	15 (23.8)
Adjuvant chemotherapy n (%)	21 (33.3)
Previous surgery n (%)^a	4 (6.3)
Multicentric/multifocal disease n (%)^a	23 (33.3)
Hormone receptor status positive n (%)^a	51 (73.9)
Clinical presentation (palpable/not palpable)^a	42/32

^aValues according to Ethos.

Table 1.

Open in new tab

Patients and Disease Characteristics

Patient and disease characteristics	Value
Age, years (range)^a	49 (21-69)
Mean BMI (kg/m²)^a	22
Current smoking history n (%)^a	6 (9.5)
Diabetes n (%)^a	8 (10)
Axillary lymph node dissection n (%)	18 (28.5)
Previous radiotherapy n (%)^a	4 (5.4)
Post mastectomy radiotherapy n (%)	11 (14.8)
Neoadjuvant chemotherapy n (%)	15 (23.8)
Adjuvant chemotherapy n (%)	21 (33.3)
Previous surgery n (%)^a	4 (6.3)
Multicentric/multifocal disease n (%)^a	23 (33.3)
Hormone receptor status positive n (%)^a	51 (73.9)
Clinical presentation (palpable/not palpable)^a	42/32

Patient and disease characteristics	Value
Age, years (range)^a	49 (21-69)
Mean BMI (kg/m²)^a	22
Current smoking history n (%)^a	6 (9.5)
Diabetes n (%)^a	8 (10)
Axillary lymph node dissection n (%)	18 (28.5)
Previous radiotherapy n (%)^a	4 (5.4)
Post mastectomy radiotherapy n (%)	11 (14.8)
Neoadjuvant chemotherapy n (%)	15 (23.8)
Adjuvant chemotherapy n (%)	21 (33.3)
Previous surgery n (%)^a	4 (6.3)
Multicentric/multifocal disease n (%)^a	23 (33.3)
Hormone receptor status positive n (%)^a	51 (73.9)
Clinical presentation (palpable/not palpable)^a	42/32

^aValues according to Ethos.